dc.contributor.author
Stiebel-Kalish, Hadas
dc.contributor.author
Rubarth, Kerstin
dc.contributor.author
Shouchane-Blum, Karny
dc.contributor.author
Tiosano, Alon
dc.contributor.author
Lotan, Itay
dc.contributor.author
Hellmann, Mark A.
dc.contributor.author
Wilf-Yarkoni, Adi
dc.contributor.author
Bialer, Omer
dc.contributor.author
Flanagan, Eoin P.
dc.contributor.author
Pittock, Sean J.
dc.contributor.author
Bhatti, M. Tariq
dc.contributor.author
Schmitz-Hübsch, Tanja
dc.contributor.author
Paul, Friedemann
dc.contributor.author
Asseyer, Susanna
dc.contributor.author
Chen, John J.
dc.date.accessioned
2024-07-22T13:43:21Z
dc.date.available
2024-07-22T13:43:21Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/44281
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-43992
dc.description.abstract
Optic neuritis (ON) is a frequent presentation at onset of multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The pathophysiology underlying these diseases, especially MOGAD, is still being elucidated. While obesity has been reported to potentially be a risk factor for MS, this has not been explored in NMOSD or MOGAD. We aimed to investigate a possible association between obesity (body mass index [BMI]>30 kg/m(2)) in patients with MOGAD, aquaporin 4-IgG positive NMOSD (AQP4-IgG+NMOSD) or MS. In this multicenter non-interventional retrospective study, data was collected from patients with a first ever demyelinating attack of ON subsequently diagnosed with MOGAD (n=44), AQP4-IgG+NMOSD (n=49) or MS (n=90) between 2005 and 2020. The following data was collected: age, sex, ethnicity, BMI (documented before corticosteroid treatment), and the ON etiology after diagnostic work-up. A mixed model analysis was performed to assess the potential of obesity or BMI to predict MOGAD-ON, and to distinguish MOGAD-ON from AQP4-IgG+NMOSD-ON and MS-ON. Main outcome measures included BMI in patients with acute ON and subsequent diagnosis of MOGAD, AQP4-IgG+NMOSD or MS. A higher BMI was significantly associated with a diagnosis of MOGAD-ON (p<0.001); in MOGAD patients the mean BMI was 31.6 kg/m(2) (standard deviation (SD) 7.2), while the mean BMI was 24.7 kg/m(2) (SD 5.3) in AQP4-IgG+NMOSD patients, and 26.9 kg/m(2) (SD 6.2) in MS patients. Mixed-effects multinomial logistic regression, adjusted for age and sex, with obesity as a binary variable, revealed that obesity was associated with a higher odds ratio (OR) of a subsequent MOGAD diagnosis (OR 5.466, 95% CI [2.039, 14.650], p=0.001) in contradistinction with AQP4-IgG+NMOSD. This study suggests an association between obesity and MOGAD. Our findings require further exploration, but could have significant pathophysiologic implications if confirmed in larger prospective studies.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Autoantibodies
en
dc.subject
Myelin-Oligodendrocyte Glycoprotein
en
dc.subject
Neuromyelitis Optica
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Obesity is associated with myelin oligodendrocyte glycoprotein antibody-associated disease in acute optic neuritis
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
21312
dcterms.bibliographicCitation.doi
10.1038/s41598-022-21592-8
dcterms.bibliographicCitation.journaltitle
Scientific Reports
dcterms.bibliographicCitation.number
1
dcterms.bibliographicCitation.originalpublishername
Springer Nature
dcterms.bibliographicCitation.volume
12
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
Springer Nature DEAL
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
36494385
dcterms.isPartOf.eissn
2045-2322